In 2020, the PRMT1-specific inhibitor TC-E-5003 was revealed to be an appealing anti-tumor drug preclinically, especially in combination with the chemotherapeutic drug-loaded injectable NBCA ethyl oleate implant [126]. The gene discussed is PRMT1; the disease is neoplasm.